Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Phase 2b/3 Extension Study to Assess the Safety and Efficacy of ABP-671 in Participants With Gout Who Completed the Double-blind Treatment Period in Study ABP-671-301

NCT06276556 is registered in ClinicalTrials.gov with Atom Therapeutics Co., Ltd as lead sponsor.

NCT NCT06276556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06276556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Phase 2b/3 Extension Study to Assess the Safety and Efficacy of ABP-671 in Participants With Gout Who Completed the Double-blind Treatment Period in Study ABP-671-301
Lead sponsor
Atom Therapeutics Co., Ltd
Phase
Phase 2/3
Overall status
Terminated
Start date
April 22, 2024
Completion date
September 5, 2024
Enrollment
43 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

gout